Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2011

Open Access 01-12-2011 | Research

Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients

Authors: Salvatore Caterino, Laura Lorenzon, Niccolò Petrucciani, Elsa Iannicelli, Emanuela Pilozzi, Adriana Romiti, Marco Cavallini, Vincenzo Ziparo

Published in: World Journal of Surgical Oncology | Issue 1/2011

Login to get access

Abstract

Background

Gastrointestinal stromal tumors (GIST) are mesenchymal tumors of the gastrointestinal tract, usually kit-positive, that are believed to originate from interstitial cell of Cajal, or their related stem cells. The most common clinical presentation of these tumors is gastrointestinal bleeding, otherwise they may cause intestinal obstruction, abdominal pain, a palpable mass, or can be incidentally detected during surgery or endoscopic/radiological procedures. Prognosis is related to the size of the tumor and to the mitotic rate; other prognostic factors are tumor location, tumor resection margins, tumor rupture, and c-kit mutation that may interfere with molecular target therapy efficacy.

Aim

Primary aim of this study was to report our experience regarding GIST patients, correlating symptoms at presentation with tumor localization and risk factors.

Patients and methods

47 consecutive patients undergone to surgical resection for GISTs were enrolled in a prospective study from December 1999 to March 2009. Patient's clinical and pathological features were collected and analysed.

Results

The most common symptom was abdominal pain. Bleeding in the digestive tract and abdominal pain were more frequent in gastric GISTs (58% and 61%); acute abdominal symptoms were more frequent in jejunal and ileal GISTs (40% and 60%), p < 0.05. We reported a mild correlation between the mitotic rate index and symptoms at presentation (p 0.074): this correlation was stronger if GISTs causing "acute abdominal symptoms" were compared with GISTs causing "abdominal pain" as main symptom (p 0.039) and with "incidental" GISTs (p 0.022).
We observed an higher prevalence of symptomatic patients in the "high risk/malignant group" of both the Fletcher's and Miettines's classification (p < 0.05).

Conclusion

According with our findings symptoms correlate to tumor location, to class risk criteria as mitotic index and risk classifications, however we cannot conclude that symptoms are per se predictive of survival or patient's outcome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Miettinen M, Lasota J: Gastrointestinal Stromal Tumors. Review on Morphology, Molecular pathology, Prognosis, and Differential Diagnosis. Arch Pathol Lab Med. 2006, 130 (10): 1466-78.PubMed Miettinen M, Lasota J: Gastrointestinal Stromal Tumors. Review on Morphology, Molecular pathology, Prognosis, and Differential Diagnosis. Arch Pathol Lab Med. 2006, 130 (10): 1466-78.PubMed
2.
go back to reference Miettinen M, Lasota J: Gastrointestinal Stromal Tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438: 1-12. 10.1007/s004280000338.CrossRefPubMed Miettinen M, Lasota J: Gastrointestinal Stromal Tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438: 1-12. 10.1007/s004280000338.CrossRefPubMed
3.
go back to reference Nilsson B, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer. 2005, 103: 821-829. 10.1002/cncr.20862.CrossRefPubMed Nilsson B, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer. 2005, 103: 821-829. 10.1002/cncr.20862.CrossRefPubMed
4.
go back to reference Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC: Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003, 226: 527-532. 10.1148/radiol.2262011880.CrossRefPubMed Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC: Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003, 226: 527-532. 10.1148/radiol.2262011880.CrossRefPubMed
5.
go back to reference Duffaud F, Blay JY: Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003, 65: 187-197. 10.1159/000074470.CrossRefPubMed Duffaud F, Blay JY: Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003, 65: 187-197. 10.1159/000074470.CrossRefPubMed
6.
go back to reference De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.CrossRef De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.CrossRef
7.
go back to reference Lewis JJ, Brennan MF: Soft tissue sarcomas. Curr Probl Surg. 1996, 33: 817-872. 10.1016/S0011-3840(96)80013-X.CrossRefPubMed Lewis JJ, Brennan MF: Soft tissue sarcomas. Curr Probl Surg. 1996, 33: 817-872. 10.1016/S0011-3840(96)80013-X.CrossRefPubMed
8.
go back to reference Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function muatations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577.CrossRefPubMed Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function muatations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577.CrossRefPubMed
9.
go back to reference Kitamura Y, Hirota S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004, 61: 2924-2931. 10.1007/s00018-004-4273-y.CrossRefPubMed Kitamura Y, Hirota S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004, 61: 2924-2931. 10.1007/s00018-004-4273-y.CrossRefPubMed
10.
go back to reference Pawson T: Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002, 38 (Suppl 5): S3-S10. 10.1016/S0959-8049(02)80597-4.CrossRefPubMed Pawson T: Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002, 38 (Suppl 5): S3-S10. 10.1016/S0959-8049(02)80597-4.CrossRefPubMed
11.
go back to reference Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61: 8118-8121.PubMed Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61: 8118-8121.PubMed
12.
go back to reference Reith JD, Goldblum JR, Lyles RH, Weiss SW: Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000, 13: 577-585. 10.1038/modpathol.3880099.CrossRefPubMed Reith JD, Goldblum JR, Lyles RH, Weiss SW: Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000, 13: 577-585. 10.1038/modpathol.3880099.CrossRefPubMed
13.
go back to reference Lee CH, Liang CW, Espinosa I: The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol. 2010, 17 (3): 222-32. 10.1097/PAP.0b013e3181d973c2.CrossRefPubMed Lee CH, Liang CW, Espinosa I: The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol. 2010, 17 (3): 222-32. 10.1097/PAP.0b013e3181d973c2.CrossRefPubMed
14.
go back to reference Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. Eur J Cancer. 2002, 38: S39-51. 10.1016/S0959-8049(02)80602-5.CrossRefPubMed Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. Eur J Cancer. 2002, 38: S39-51. 10.1016/S0959-8049(02)80602-5.CrossRefPubMed
15.
go back to reference Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smoothmuscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol. 1999, 23: 82-87. 10.1097/00000478-199901000-00009.CrossRefPubMed Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smoothmuscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol. 1999, 23: 82-87. 10.1097/00000478-199901000-00009.CrossRefPubMed
16.
go back to reference Gupta P, Tewari M, Shukla HS: Gastrointestinal stromal tumor. Surg Oncol. 2008, 17: 129-138. 10.1016/j.suronc.2007.12.002.CrossRefPubMed Gupta P, Tewari M, Shukla HS: Gastrointestinal stromal tumor. Surg Oncol. 2008, 17: 129-138. 10.1016/j.suronc.2007.12.002.CrossRefPubMed
17.
go back to reference ESMO Guidelines Working Group, Blay JY, Le Cesne A: Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007, 18 (Suppl 2): ii27-9. ESMO Guidelines Working Group, Blay JY, Le Cesne A: Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007, 18 (Suppl 2): ii27-9.
18.
go back to reference Lopez M, Comandone A, Adamo V, Apice G, Bearzi I, Bracci R, Carlini M, Carpano S, Condorelli S, Covello R, Cucchiara G, Di Filippo F, Doglietto GB, Ficorella C, Garofalo A, Gebbia N, Giuliani F, Massidda B, Messerini L, Palmirotta R, Tonelli F, Vidiri A: Raccomandazioni cliniche per la diagnosi, la terapia ed il follow-up dei tumori stromali gastrointestinali. Clin Ter. 2006, 157 (3): 283-299.PubMed Lopez M, Comandone A, Adamo V, Apice G, Bearzi I, Bracci R, Carlini M, Carpano S, Condorelli S, Covello R, Cucchiara G, Di Filippo F, Doglietto GB, Ficorella C, Garofalo A, Gebbia N, Giuliani F, Massidda B, Messerini L, Palmirotta R, Tonelli F, Vidiri A: Raccomandazioni cliniche per la diagnosi, la terapia ed il follow-up dei tumori stromali gastrointestinali. Clin Ter. 2006, 157 (3): 283-299.PubMed
19.
go back to reference Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO Clinical Reccomendations for diagnosis, treatment and follow-up. Ann Oncol. 2008, 19 (Suppl 2): ii35-38. 10.1093/annonc/mdn080.PubMed Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO Clinical Reccomendations for diagnosis, treatment and follow-up. Ann Oncol. 2008, 19 (Suppl 2): ii35-38. 10.1093/annonc/mdn080.PubMed
20.
go back to reference Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344: 1052-1056. 10.1056/NEJM200104053441404.CrossRefPubMed Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344: 1052-1056. 10.1056/NEJM200104053441404.CrossRefPubMed
21.
go back to reference Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA: Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008, 3: 88-99. 10.2174/157489208784638749.CrossRefPubMed Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA: Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008, 3: 88-99. 10.2174/157489208784638749.CrossRefPubMed
22.
go back to reference Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39 (10): 1411-9. 10.1016/j.humpath.2008.06.025.CrossRefPubMed Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39 (10): 1411-9. 10.1016/j.humpath.2008.06.025.CrossRefPubMed
23.
go back to reference Zhang L, Smyrki TC, Young WF, Stratakis CA, Carney JA: Gastrointestinal stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010, 34 (1): 53-64. 10.1097/PAS.0b013e3181c20f4f.PubMedCentralCrossRefPubMed Zhang L, Smyrki TC, Young WF, Stratakis CA, Carney JA: Gastrointestinal stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010, 34 (1): 53-64. 10.1097/PAS.0b013e3181c20f4f.PubMedCentralCrossRefPubMed
24.
go back to reference Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26 (4): 620-5. 10.1200/JCO.2007.13.4403.CrossRefPubMed Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26 (4): 620-5. 10.1200/JCO.2007.13.4403.CrossRefPubMed
25.
go back to reference Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Can Res. 2006, 12 (6): 1743-1749. 10.1158/1078-0432.CCR-05-1211.CrossRef Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Can Res. 2006, 12 (6): 1743-1749. 10.1158/1078-0432.CCR-05-1211.CrossRef
26.
go back to reference Bulusu VR, Jephcott CR, Fawcett S, Cook N, Hatcher H, Moyle P, Carroll N, Earl H, Save V, Hardwick R: RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumors (GISTs) on imatinib mesylate. Cambridge GIST study group experience. J Clin Oncol ASCO MEETING ABSTRACTS. 2007, 25 (18 S): 10019- Bulusu VR, Jephcott CR, Fawcett S, Cook N, Hatcher H, Moyle P, Carroll N, Earl H, Save V, Hardwick R: RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumors (GISTs) on imatinib mesylate. Cambridge GIST study group experience. J Clin Oncol ASCO MEETING ABSTRACTS. 2007, 25 (18 S): 10019-
27.
go back to reference Fletcher C, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors; a consensus approach. Human Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.CrossRef Fletcher C, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors; a consensus approach. Human Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.CrossRef
28.
go back to reference Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23: 70-83. 10.1053/j.semdp.2006.09.001.CrossRefPubMed Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23: 70-83. 10.1053/j.semdp.2006.09.001.CrossRefPubMed
29.
go back to reference Liu YJ, Yang Z, Hao LS, Xia L, Jia QB, Wu XT: Synchronous incidental gastrointestinal stromal and epithelial malignant tumors. World J Gastroenterol. 2009, 15 (16): 2027-2031. 10.3748/wjg.15.2027.PubMedCentralCrossRefPubMed Liu YJ, Yang Z, Hao LS, Xia L, Jia QB, Wu XT: Synchronous incidental gastrointestinal stromal and epithelial malignant tumors. World J Gastroenterol. 2009, 15 (16): 2027-2031. 10.3748/wjg.15.2027.PubMedCentralCrossRefPubMed
30.
go back to reference Horowitz J, Spellman JE, Driscoll DL, Velez AF, Karakousis CP: An institutional review of sarcomas of the large and small intestine. J Am Coll Surg. 1995, 180: 465-71.PubMed Horowitz J, Spellman JE, Driscoll DL, Velez AF, Karakousis CP: An institutional review of sarcomas of the large and small intestine. J Am Coll Surg. 1995, 180: 465-71.PubMed
31.
go back to reference DeMatteo RP: The GIST targeted cancer therapy: a tumor (gastrointestinal stromal tumor) a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002, 9 (9): 831-839. 10.1007/BF02557518.CrossRefPubMed DeMatteo RP: The GIST targeted cancer therapy: a tumor (gastrointestinal stromal tumor) a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002, 9 (9): 831-839. 10.1007/BF02557518.CrossRefPubMed
32.
go back to reference Scarpa M, Bertin M, Ruffolo C, Polese L, D'Amico DF, Angriman I: A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008, 98: 384-392. 10.1002/jso.21120.CrossRefPubMed Scarpa M, Bertin M, Ruffolo C, Polese L, D'Amico DF, Angriman I: A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008, 98: 384-392. 10.1002/jso.21120.CrossRefPubMed
33.
go back to reference El-Zohairy M, Khalil el-SA, Fakhr I, El-Shahawy M, Gouda I: Gastrointestinal stromal tumor (GIST)'s surgical treatment, NCI experience. J Egypt Natl Canc Inst. 2005, 17: 56-66.PubMed El-Zohairy M, Khalil el-SA, Fakhr I, El-Shahawy M, Gouda I: Gastrointestinal stromal tumor (GIST)'s surgical treatment, NCI experience. J Egypt Natl Canc Inst. 2005, 17: 56-66.PubMed
34.
go back to reference Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001, 136: 383-389. 10.1001/archsurg.136.4.383.CrossRefPubMed Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001, 136: 383-389. 10.1001/archsurg.136.4.383.CrossRefPubMed
35.
go back to reference Darnell A, Dalmau E, Pericay C, Musulén E, Martín J, Puig J, Malet A, Saigí E, Rey M: Gastrointestinal stromal tumors. Abdom Imaging. 2006, 31: 387-399. 10.1007/s00261-004-0092-8.CrossRefPubMed Darnell A, Dalmau E, Pericay C, Musulén E, Martín J, Puig J, Malet A, Saigí E, Rey M: Gastrointestinal stromal tumors. Abdom Imaging. 2006, 31: 387-399. 10.1007/s00261-004-0092-8.CrossRefPubMed
36.
go back to reference Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S: Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol. 2004, 30: 1098-1103. 10.1016/j.ejso.2004.06.016.CrossRefPubMed Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S: Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol. 2004, 30: 1098-1103. 10.1016/j.ejso.2004.06.016.CrossRefPubMed
37.
go back to reference Rajappa S, Muppavarapu KM, Uppin S, Digumarti R: Gastrointestinal stromal tumors: a single institution experience of 50 cases. Indian J Gastroenterol. 2007, 26: 225-229.PubMed Rajappa S, Muppavarapu KM, Uppin S, Digumarti R: Gastrointestinal stromal tumors: a single institution experience of 50 cases. Indian J Gastroenterol. 2007, 26: 225-229.PubMed
38.
go back to reference Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG: Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005, 117: 289-293. 10.1002/ijc.21167.CrossRefPubMed Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG: Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005, 117: 289-293. 10.1002/ijc.21167.CrossRefPubMed
39.
go back to reference Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK: Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008, 15 (8): 2153-63. 10.1245/s10434-008-9969-z.CrossRefPubMed Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK: Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008, 15 (8): 2153-63. 10.1245/s10434-008-9969-z.CrossRefPubMed
40.
go back to reference Ahmed I, Welch NT, Parsons SL: Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol. 2008, 34: 445-449.CrossRefPubMed Ahmed I, Welch NT, Parsons SL: Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol. 2008, 34: 445-449.CrossRefPubMed
41.
go back to reference Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH, Schleck CD, Hodge DO, Donohue JH: Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008, 15: 52-59. 10.1245/s10434-007-9633-z.CrossRefPubMed Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH, Schleck CD, Hodge DO, Donohue JH: Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008, 15: 52-59. 10.1245/s10434-007-9633-z.CrossRefPubMed
42.
go back to reference Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG: Surgery of the residual disease following molecular-target therapy with imatinib mesylate in advanced/matastatic GIST. Ann Surg. 2007, 245 (3): 341-346. 10.1097/01.sla.0000242710.36384.1b.PubMedCentralCrossRefPubMed Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG: Surgery of the residual disease following molecular-target therapy with imatinib mesylate in advanced/matastatic GIST. Ann Surg. 2007, 245 (3): 341-346. 10.1097/01.sla.0000242710.36384.1b.PubMedCentralCrossRefPubMed
43.
go back to reference Iwahashi M, Takifuji K, Ojima T, Nakamura M, Nakamori M, Nakatani Y, Ueda K, Ishida K, Naka T, Ono K, Yamaue H: Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg. 2006, 30: 28-35. 10.1007/s00268-005-7944-4.CrossRefPubMed Iwahashi M, Takifuji K, Ojima T, Nakamura M, Nakamori M, Nakatani Y, Ueda K, Ishida K, Naka T, Ono K, Yamaue H: Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg. 2006, 30: 28-35. 10.1007/s00268-005-7944-4.CrossRefPubMed
44.
go back to reference Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CDM, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PWT, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J: NCCN Task Force Report: Optimal management of patients with Gastrointestinal Stromal Tumor (GIST--Update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2007, 5 (Suppl 2): S1-29.PubMed Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CDM, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PWT, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J: NCCN Task Force Report: Optimal management of patients with Gastrointestinal Stromal Tumor (GIST--Update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2007, 5 (Suppl 2): S1-29.PubMed
45.
go back to reference Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PWT, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD: NCCN Task Force Report: Update on the management of patients with Gastrointestinal Stromal Tumors. J Natl Compr Canc Netw. 2010, 8 (Suppl 2): S1-41.PubMedCentralPubMed Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PWT, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD: NCCN Task Force Report: Update on the management of patients with Gastrointestinal Stromal Tumors. J Natl Compr Canc Netw. 2010, 8 (Suppl 2): S1-41.PubMedCentralPubMed
Metadata
Title
Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients
Authors
Salvatore Caterino
Laura Lorenzon
Niccolò Petrucciani
Elsa Iannicelli
Emanuela Pilozzi
Adriana Romiti
Marco Cavallini
Vincenzo Ziparo
Publication date
01-12-2011
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2011
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-9-13

Other articles of this Issue 1/2011

World Journal of Surgical Oncology 1/2011 Go to the issue